AMINOSYN-RF 5.2%
Clinical safety rating
cautionComprehensive clinical and safety monograph for AMINOSYN-RF 5.2% (AMINOSYN-RF 5.2%).
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
| Metabolism | Amino acids undergo hepatic deamination and transamination; nitrogen is converted to urea via the urea cycle (hepatic) and excreted renally. The product's composition aims to reduce ureagenesis. |
| Excretion | Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%). |
| Half-life | The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes. |
| Protein binding | Amino acids show minimal protein binding (<5%); not bound to albumin or globulins to a significant extent. |
| Volume of Distribution | Approximately 0.2–0.3 L/kg, reflecting distribution mainly into extracellular fluid and lean tissues; total body water is about 0.6 L/kg, but amino acids are rapidly taken up by cells. |
| Bioavailability | Intravenous: 100% (complete bioavailability); not absorbed orally or via other routes. |
| Onset of Action | Intravenous: immediate metabolic effects within minutes; serum amino acid levels rise during infusion. |
| Duration of Action | Duration persists as long as infusion continues; after discontinuation, metabolic effects wane within 1–2 hours as amino acids clear. |
| Molecular Weight | 75.07 |
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 mL to 1000 mL/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 25 mL/min: reduce dose to 0.5-0.8 g/kg/day and monitor BUN and electrolytes. In patients on dialysis, provide 1.0-1.2 g/kg/day postpartum. Not recommended with GFR < 15 mL/min unless on renal replacement therapy. |
| Liver impairment | Child-Pugh Class B or C: avoid use due to risk of hyperammonemia and encephalopathy. For mild impairment, use with caution and monitor ammonia levels; dose reduction may be needed. |
| Pediatric use | Neonates and infants: 1.5-3.0 g/kg/day intravenously. Children: 1.0-2.0 g/kg/day. Adjust based on metabolic requirements and tolerance. Administer as part of parenteral nutrition. |
| Geriatric use | Initiate at lower end of dosing range (1.0-1.2 g/kg/day) due to decreased renal function. Monitor serum creatinine and fluid balance. Adjust as needed. |
| 1st trimester | No adequate studies in pregnant women; use only if clearly needed. Animal studies not available. |
| 2nd trimester | No adequate studies in pregnant women; use only if clearly needed. |
| 3rd trimester | No adequate studies in pregnant women; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN-RF 5.2% (AMINOSYN-RF 5.2%).
| Placental transfer | Not studied; likely crosses placenta due to small molecule size and essential nutrient nature. |
| Breastfeeding | It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Aminosyn-RF 5.2% is administered to a nursing woman. |
| Lactation Rating | L3 |
| Teratogenic Risk | Aminosyn-RF 5.2% is an amino acid solution used for parenteral nutrition. There are no adequate studies in pregnant women. Animal reproduction studies have not been conducted. Theoretical risks include amino acid imbalances affecting fetal development if maternal nutrition is compromised. Generally, IV amino acids are used during pregnancy only if clearly needed, and benefits may outweigh risks in malnourished mothers. First trimester: avoid unless essential. Second/third trimester: use with caution, monitor fetal growth. Peripartum: risk of maternal fluid/electrolyte imbalances affecting fetus. |
| Fetal Monitoring | Monitor maternal serum electrolytes, BUN, creatinine, ammonia, glucose, and acid-base status. Assess fluid balance to avoid overload. Monitor fetal growth via ultrasound if prolonged use. In neonate, monitor for signs of electrolyte or metabolic disturbances if mother received near term. |
| Fertility Effects | No specific data on fertility effects. In theory, severe malnutrition corrected by parenteral nutrition may improve fertility. No known direct adverse effects on gametogenesis or implantation. |
■ FDA Black Box Warning
Not for intravenous administration to patients with inborn errors of amino acid metabolism, severe hepatic failure, or hemodialysis-dependent patients with hyperammonemia.
| Serious Effects |
Hepatic comaSevere electrolyte imbalancesSevere metabolic acidosisInborn errors of amino acid metabolismAnuria or oliguria
| Precautions | Monitor serum electrolytes, acid-base balance, and renal function closely; risk of hyperkalemia, hyperammonemia, and fluid overload; not indicated for anuric patients not on dialysis; use with caution in patients with hepatic impairment. |
| Food/Dietary | Patients receiving Aminosyn-RF 5.2% are typically on a protein-restricted diet. Concurrent oral intake of high-protein foods or supplements may increase nitrogen waste and should be avoided unless prescribed. Limited fluid intake may be necessary. Consult a renal dietitian for specific dietary adjustments. |
| Clinical Pearls | Aminosyn-RF 5.2% is a renal-specific amino acid solution containing essential amino acids and histidine, designed for patients with acute or chronic renal failure to reduce nitrogen load. Monitor serum electrolytes, BUN, creatinine, ammonia, and acid-base status. Use with caution in patients with metabolic acidosis or hyperammonemia. Do not administer simultaneously with blood products via same IV line. Ensure adequate caloric intake to prevent utilization of amino acids for energy. |
| Patient Advice | This medication is a sterile amino acid solution given intravenously to provide protein for patients with kidney problems. · It is usually administered in a hospital setting under close medical supervision. · Your healthcare team will monitor your kidney function, electrolyte levels, and other lab values regularly. · Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing) or infusion site reactions immediately. · This solution does not contain all necessary nutrients; you may require additional supplements or a special diet. |
Loading safety data…